An interventional study of Body trimmer intervention dose 1 and Body trimmer intervention dose 2 in Abdominal Obesity, sponsored by Amway (China) R&D Center. Recruiting at 1 site in China. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Amway (China) R&D Center · Not applicable, Interventional, and Other
The goal of this clinical trial is to explore the weight loss effect of Amway "BODY TRIMMER" on study participants with abdominal obesity. The main questions it aim to answer is:
Does Amway "BODY TRIMMER" reduce the weight of Study participants? Researchers will compare both high and low dosage groups (after taking Amway "BODY TRIMMER" ) to observe the improvement of weight loss indicators in abdominal obesity.
Participants will:
Take Amway "BODY TRIMMER" every day for 3 months. Regularly report on three meals. Visit the clinic once every 4 weeks for checkups and tests.
294 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.
This study's planned enrollment of 110 is above the median of 58 across 234 interventional studies indexed under Obesity, Abdominal.
Browse Obesity, Abdominal studies →Amway (China) R&D Center is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects maintain their usual diet and daily lifestyle, and no investigational product is administered during the study period.
Amway "BODY TRIMMER", oral powder, 1 sachet administered once daily.
Other: Body trimmer intervention dose 1
Amway "BODY TRIMMER", oral powder, 2 sachets administered once daily.
Other: Body trimmer intervention dose 2
Amway "BODY TRIMMER"
Amway "BODY TRIMMER"
Weight
Changes from weight in the high-dose, low-dose and blank control groups.
Time frame: baseline day 0,week4,week8,week12
Blood Pressure
Between-group changes across the high-dose group, low-dose group, and blank control group at baseline, 4-week, 8-week, and 12-week follow-up; within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be measured.
Time frame: baseline day 0,week4,week8,week12
BMI (Body Mass Index)
Between-group changes across the high-dose group, low-dose group, and blank control group at baseline, 4-week, 8-week, and 12-week follow-up; within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up.
Time frame: baseline day 0,week4,week8,week12
Improvement of Fat and Muscle Portions and Body Fat Percentage measured by Inbody S10 or S770 from baseline
Body composition consists of specific body components including fat, protein, minerals and body water measured by Inbody S10 or S770.Within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up; between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Changes from baseline in abdominal fat (Android fat % and Gynoid fat %) measured by dual-energy X-ray absorptiometry (DXA).
Within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up; between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Blood Lipids
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Blood Glucose
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Serum Insulin
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
C-reactive protein (CRP)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
1L-6
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Glycated Hemoglobin (HbA1c)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Appetite Visual Analogue Scale (VAS)
Visual Analogue Scale (VAS) The VAS was used to assess satiety, with scores ranging from 0 to 30 points. * 0-10 points: Good satiety: moderate appetite, weak hunger sensation, low food intake, favorable for weight loss * 11-20 points: Moderate satiety: balanced appetite and hunger, normal food intake, generally controllable * 21-30 points: Poor satiety: strong appetite, intense hunger sensation, large food intake, unfavorable for weight loss
Time frame: baseline day 0,week4,week8,week12
Dietary Pattern and Fat Intake Assessment (total score: 10-40 points)
* 35-40 points: Excellent diet Regular and healthy dietary pattern, low oil and sugar intake, sufficient vegetable consumption, limited high-fat foods * 28-34 points: Good diet Generally healthy diet; fat and snack intake are manageable * 20-27 points: Fair diet Relatively high fat intake; frequent take-out meals and snacks; dietary adjustments are needed * 10-19 points: Poor diet High-oil and high-sugar diet; frequent take-out and fried foods; major barriers to weight loss
Time frame: baseline day 0,week4,week8,week12
Physical Activity Assessment (total score: 3-12 points)
* 10-12 points: Excellent physical activity Regular exercise with adequate duration and high daily activity level * 7-9 points: Good physical activity Established exercise habits; activity levels meet requirements * 5-6 points: Fair physical activity Occasional exercise; predominantly sedentary daily lifestyle * 3-4 points: Poor physical activity Virtually no exercise; prolonged sedentary behavior; insufficient energy expenditure
Time frame: baseline day 0,week4,week8,week12
Alanine Aminotransferase (ALT)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Aspartate Aminotransferase (AST)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Alkaline Phosphatase (ALP)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Gamma-Glutamyl Transferase (GGT)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Total Bilirubin (TBIL)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Direct Bilirubin (DBIL)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Total Protein (TP)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Uric Acid
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Serum Creatinine (Scr)
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Serum Urea
Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up.
Time frame: baseline day 0,week12
Waist Circumference
Waist circumference measured by soft tape measure, unit: cm.
Time frame: baseline day 0,week4,week8,week12
Hip Circumference
Hip circumference measured by soft tape measure, unit: cm.
Time frame: baseline day 0,week4,week8,week12
Thigh Circumference
Thigh circumference measured by soft tape measure, unit: cm.
Time frame: baseline day 0,week4,week8,week12
Upper-arm Circumference
Upper-arm circumference measured by soft tape measure, unit: cm.
Time frame: baseline day 0,week4,week8,week12
Waist-to-Hip Ratio
Ratio of waist circumference to hip circumference, dimensionless.
Time frame: baseline day 0,week4,week8,week12
Changes in the Abundance of Gut Microbiota in Feces
Changes and differences at 12-week follow-up.To investigate changes in the relative abundance of microbial communities as determined by 16S rRNA sequencing analysis and differences in the absolute abundance of specific microbial communities as determined by qPCR quantification
Time frame: baseline day 0,week12
Changes in Metabolic Byproducts in Feces
Changes and differences at 12-week follow-up. Quantitative analysis of fecal metabolites including lactic acid, palmitoylcarnitine, glutamine, and oleoylcarnitine is performed using ultra-high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Time frame: baseline day 0,week12
Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.
Of 116 interventional studies with no phase under Obesity, Abdominal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amway (China) R&D Center